FOXO1 overexpression and loss of pSerine256-FOXO1 expression predicts clinical outcome in esophageal adenocarcinomas-Reference-Cited by-同舟云学术

FOXO1 overexpression and loss of pSerine256-FOXO1 expression predicts clinical outcome in esophageal adenocarcinomas

Published:2018-11-26 Issue:1 Volume:8 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Grupp Katharina,Uzunoglu Faik Güntac,Melling Nathaniel,Hofmann Bianca,El Gammal Alexander Tarek,Grotelüschen Rainer,Heumann Asmus,Bellon Eugen,Reeh Matthias,Wolters-Eisfeld Gerrit,Ghabdan Tarik,Nentwich Michael,Bachmann Kai,Bockhorn Maximillian,Bogoevski Dean,Izbicki Jakob Robert,Kutup Asad

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-018-35459-4.pdf

Reference60 articles.

1. Song, Y. et al. Identification of genomic alterations in oesophageal squamous cell cancer. Nature 509, 91–95 (2014).

2. Creemers, A. et al. A systematic review and meta-analysis of prognostic biomarkers in resectable esophageal adenocarcinomas. Scientific reports 8, 13281 (2018).

3. Wang, C., Wang, J., Chen, Z., Gao, Y. & He, J. Immunohistochemical prognostic markers of esophageal squamous cell carcinoma. A systematic review. Chinese journal of cancer 36, 65 (2017).

4. Bartley, A. N. et al. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma. Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Archives of pathology & laboratory medicine 140, 1345–1363 (2016).

5. Bang, Y.-J. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA). A phase 3, open-label, randomised controlled trial. Lancet (London, England) 376, 687–697 (2010).

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Comprehensive Analysis of Tn and STn Antigen Expression in Esophageal Adenocarcinoma;Cancers;2024-01-05

2. PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma;Blood Advances;2023-10-13

3. Mechanism of forkhead transcription factors binding to a novel palindromic DNA site;Nucleic Acids Research;2021-02-12